Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Cyto/hemocompatible magnetic hybrid NPs made of iron oxide/silver sulfide quantum dots with luminescence in the near-infrared region for combinational therapy of peritoneal metastasis

Objetivo

Peritoneal metastasis (PM) is considered as the terminal stage of metastatic colon cancer, with still poor median survival rate even with the best recent chemotherapy (Chem) treatment suggesting the need for advanced methods to assist with the early diagnosis and treatment. However, the newest methods combine cytoreductive surgery with hyperthermic intraperitoneal Chem (HIPEC), which uses mild hyperthermia (Hyp) by circulation of a hot fluid to boost the diffusion and cytotoxic effect of drugs. A recent development in patients with unresectable PM is pressurized intraperitoneal aerosol Chem (PIPAC) that combines a diagnostic laparoscopy with locoregional administration of Chem as an aerosol. Non-selective biodistribution, low bioavailability, high drug concentrations, limited drug circulation time, and various side-effects limit the utilisation of HIPEC and PIPAC. Innovative drug delivery system with the controlled drug release at tumour site can enhance the therapeutic efficacy. Utilisation of nanoparticles (NPs) as carriers to deliver drugs with the possibility of tagging them with targeting agents will overcome the off-site toxicity. Cyto/hemocompatible magnetic hybrid NPs (Silver sulphide-Iron oxide) with luminescence in the near-infrared region for combinational therapy of peritoneal metastasis (SANTE) project aims to develop multimodal therapy approach for diagnosis and treatment of PM. It intends to enhance the efficacy of PM treatment using a combination of image guided remotely activated nanoHyp coupled with targeted Chem. Tumour targeted Ag2S will allow preoperative detection of microscopic or residual tumours to improve resection before Chem/Hyp. Iron oxide, targeting agent(cetuximab), and the chemotherapeutic drug(cisplatin) are all clinically used for the treatment of various type of cancers. The result of this fellowship will enable scientists in the PM field to translate the novel diagnostic and therapeutic methods into clinical practice and market.a

Ámbito científico (EuroSciVoc)

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) HORIZON-MSCA-2022-PF-01

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

UNIVERSITE PARIS CITE
Aportación neta de la UEn
€ 211 754,88
Dirección
85 BD SAINT GERMAIN
75006 Paris
Francia
Región
Ile-de-France Ile-de-France Paris
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
Sin datos

Socios (2)